GleamWall
中文EN

PMCB PharmaCyte Biotech, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1157075 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-1,334.7%
TTM EPS YoY-3,566.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.4%
ROA-39.5%
ROIC (approx.)-27.6%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets18.8%
Debt / equity0.00x
Current ratio40.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.24x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30
Income statement
Revenue$0$0
R&D expense$391,301$438,416
SG&A expense$4.91M$3.94M
Operating income-$6.85M-$4.38M
Pretax income-$19.42M$30.66M
Income tax$0$0
Net income-$19.42M$30.66M
EPS (basic)-2.773.19
EPS (diluted)-2.773.19
Weighted avg. shares (diluted)8.38M7.33M
Balance sheet
Cash & equivalents$18.60M$15.17M
Short-term investments$254,010$366,316
Current assets$37.42M$22.38M
Intangibles$0$1.55M
Total assets$46.75M$55.17M
Current liabilities$826,424$2.91M
Total liabilities$11.77M$3.28M
Shareholders' equity$33.29M$51.89M
Shares outstanding10.74M6.80M
Cash flow statement
Operating cash flow-$5.15M-$2.98M
Investing cash flow$2.00M-$7.00M
Financing cash flow$6.58M-$25.03M
Stock-based compensation$892,500$0
Share buybacks$401,625$2.54M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.